+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

DTx in Medical - US Thematic Research

  • PDF Icon


  • 38 Pages
  • February 2024
  • Region: United States
  • GlobalData
  • ID: 5943554

Digital therapeutics (DTx) are software-based interventions that deliver evidence-based therapeutic interventions to patients. The interventions are driven by high-quality software programs to prevent, manage, or treat a medical condition. DTx can be prescribed on their own, or together with other therapies or devices to optimize health outcomes. The majority of DTx are designed for chronic conditions, respiratory conditions, and mental health or neurological conditions. The use of DTx generally requires a prescription, as the interventions must be cleared or certified by regulatory bodies to support their claims. The DTx market is projected to grow at a compound annual growth rate (CAGR) of 25% from 2022 to 2030 in the US.

DTx are a rapidly growing part of digital health

  • Interoperability standards and protocols enable DTx to share data with other digital health tools and platforms. As such, DTx are designed to seamlessly integrate with digital health devices and tools such as electronic medical record (EMR) systems and the broader healthcare system. Many DTx leverage data from wearable devices and sensors to monitor a patient’s health in real time, and some come in the form of mHealth apps, allowing DTx to integrate easily into telemedicine platforms. DTx aim to provide connected and comprehensive workflows that provide clinical insights.
  • DTx can improve patient care
  • DTx can provide clinical interventions directly to patients through software to treat, manage, and prevent a large spectrum of diseases. They enable the remote patient monitoring of patients, allowing healthcare professionals to track their progress and treatment plans, as well as identify potential issues in real time. DTx generate large amounts of data, and the insights derived from that data help healthcare providers to make informed decisions, identify patterns, and optimize treatment strategies for better patient outcomes.


  • This report is a thematic brief, which identifies those companies most likely to succeed in a world filled with disruptive threats. Inside, we predict how each theme will evolve and identify the leading and disrupting companies.
  • The report covers the digital therapeutics theme.

Reasons to Buy

  • The publisher's thematic research ecosystem is a single, integrated global research platform that provides an easy-to-use framework for tracking all themes across all companies in all sectors. It has a proven track record of identifying the important themes early, enabling companies to make the right investments ahead of the competition, and secure that all-important competitive advantage.
  • Develop and design your corporate strategies through an in-house expert analysis of digital therapeutics by understanding the primary ways in which this theme is impacting the healthcare industry.
  • Stay up to date on the industry’s major players and where they sit in the value chain.
  • Identify emerging industry trends to gain a competitive advantage.

Table of Contents

  • Executive Summary
  • Players
  • Thematic briefing
  • Trends
  • Industry analysis
  • Signals
  • Value Chain
  • Companies
  • Sector Scorecard
  • Glossary
  • Further Reading
  • Thematic Research Methodology
  • About the Publisher
  • Contact the Publisher

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Omada Health
  • Twill
  • Teledoc Health
  • Voluntis
  • Sword Health
  • Click Therapeutics
  • WellDoc
  • Biofourmis
  • DarioHealth
  • Kaia Health
  • Noom
  • ResMed
  • Adherium
  • Pulmonx
  • AstraZeneca
  • Akili Interactive
  • Big Health